HK Stock Market Move | CSTONE PHARMA-B(02616) rose by over 6%, and the drug SULIGLICAN monoclonal antibody was recently included in the European Society for Medical Oncology guidelines.

CSTONE PHARMA-B(02616) rose by more than 6%, reaching 5.81% as of the time of publication, with a price of 3.28 Hong Kong dollars and a turnover of 195.728 million Hong Kong dollars. On the news front, CStone Pharma announced that its flagship product, Sugletuzumab (Telisotuzumab), has been included in the "European Society of Medical Oncology Guidelines for the Dynamic Clinical Management of Non-Drive Gene Positive Metastatic Non-Small Cell Lung Cancer", and has become a first-line treatment recommended for both squamous and non-squamous non-small cell lung cancer, with high clinical benefits. Goldman Sachs recently released a research report stating that among many innovative projects, the innovative antibody-drug conjugate CS5001 (ROR1 ADC) under CStone Pharma has attracted attention. The market expects the company to announce the clinical data of CS5001 at the 2025 American Society of Clinical Oncology Annual Meeting, and actively seek licensing partnerships globally. Goldman Sachs believes that CS5001 is one of the anticipated BD projects in 2025, with high predictability of BD, a total addressable market TAM of 43 billion US dollars globally, huge potential, and CStone Pharma has obvious competitive advantages in this field, with active BD collaborations. In response, Goldman Sachs raised the company's target price and listed ROR1 and Triple Antibody as core value catalysts.